Efficacy News and Research

RSS
Kamada announces top-line results from Phase II/III trial for treatment of inherited emphysema

Kamada announces top-line results from Phase II/III trial for treatment of inherited emphysema

Data from phase III trials supports safety, efficacy of linagliptin in treating T2D in African-American adults

Data from phase III trials supports safety, efficacy of linagliptin in treating T2D in African-American adults

Bristol-Myers Squibb announces study results of nivolumab drug in patients with renal cell carcinoma

Bristol-Myers Squibb announces study results of nivolumab drug in patients with renal cell carcinoma

Telormedix completes Phase II trial of Vesimune in CIS of the bladder

Telormedix completes Phase II trial of Vesimune in CIS of the bladder

New intervention program may benefit chronically homeless, alcohol-dependent individuals

New intervention program may benefit chronically homeless, alcohol-dependent individuals

NovaBay completes enrollment of patients in global Phase 2b viral conjunctivitis trial

NovaBay completes enrollment of patients in global Phase 2b viral conjunctivitis trial

Corgenix announces that Randox received CE Mark notification for TxBCardio Assay

Corgenix announces that Randox received CE Mark notification for TxBCardio Assay

Transition Therapeutics begins TT-401 Phase 2 clinical study for treatment of type 2 diabetes

Transition Therapeutics begins TT-401 Phase 2 clinical study for treatment of type 2 diabetes

Promedior to present interim data from PRM-151 Phase 2 trial at ASCO 2014 Annual Meeting

Promedior to present interim data from PRM-151 Phase 2 trial at ASCO 2014 Annual Meeting

Global scientists to discuss latest findings on diagnosis, causes and treatments of ASD

Global scientists to discuss latest findings on diagnosis, causes and treatments of ASD

Astellas reports efficacy, safety data of isavuconazole invasive aspergillosis SECURE study at ECCMID

Astellas reports efficacy, safety data of isavuconazole invasive aspergillosis SECURE study at ECCMID

Study: Wider use of medications may help reduce substance abuse, related hospital admissions

Study: Wider use of medications may help reduce substance abuse, related hospital admissions

New technology has potential to make production of biotech medicines simpler

New technology has potential to make production of biotech medicines simpler

‘Lessebo’ effect implications for Parkinson’s therapies

‘Lessebo’ effect implications for Parkinson’s therapies

Autoimmune epilepsy diagnostics: an interview with Dr. Joseph J. Higgins, Medical Director, Neurology, Athena Diagnostics, a business of Quest Diagnostics

Autoimmune epilepsy diagnostics: an interview with Dr. Joseph J. Higgins, Medical Director, Neurology, Athena Diagnostics, a business of Quest Diagnostics

Isis Pharmaceuticals reports positive data from ISIS-GCGRRx Phase 2 study in patients with type 2 diabetes

Isis Pharmaceuticals reports positive data from ISIS-GCGRRx Phase 2 study in patients with type 2 diabetes

Nimotuzumab enhances chemo-radiosensitivity by promoting autophagic cell death in ESCC cells

Nimotuzumab enhances chemo-radiosensitivity by promoting autophagic cell death in ESCC cells

MedImmune to present Phase IIb asthma data on benralizumab and tralokinumab at ATS conference

MedImmune to present Phase IIb asthma data on benralizumab and tralokinumab at ATS conference

Patient-centered care associated with improved patient outcomes

Patient-centered care associated with improved patient outcomes

Scientists discover novel protein fragments that may protect against Alzheimer's disease

Scientists discover novel protein fragments that may protect against Alzheimer's disease

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.